LPA and myocardial infarction: A post hoc analysis from the FOURIER trial, in which 25,096 patients with stable CAD were randomized relative to evolocumab vs. placebo, showed a reduction in Lp(a) plasma levels of 27% with evolocumab associated with a significant decrease in adverse cardiovascular outcomes (composite of coronary heart disease, death, myocardial infarction, and urgent revascularization) with an absolute risk reduction of 2.49% and number needed to treat of 40 up to 3 years in patients with Lp(a) plasma values above the median 37 nmol/L serum level [68].